Skip to main content
. Author manuscript; available in PMC: 2012 Nov 28.
Published in final edited form as: Exp Biol Med (Maywood). 2011 Mar 22;236(5):537–545. doi: 10.1258/ebm.2011.010367

Figure 5. Cytotoxic activity of Brachyury-specific CTLs against tumor targets.

Figure 5

(A) Brachyury-specific, cytotoxic T lymphocytes from a normal donor were used as effectors against various tumor targets in an 111In 16-hour release assay, as indicated. The following tumor cell lines were used: H441 (HLA-A2+/Brachyury+), NCI-H460 (HLA-A2−/Brachyury+), SW1463 (HLA-A2+/Brachyury−), ASPC-1 (HLA-A2−/Brachyury−). (B) T cells derived from PBMCs of a cancer patient were used as effectors against various HLA-A2+ tumor targets, as indicated. Also shown is the expression of Brachyury and β-actin mRNA by RT-PCR in each tumor cell line. Reproduced with permission from the American Association for Cancer Research; see reference 48.